Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1470857 | 0.90 | MEN1 (0.47) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| SCHEMBL1471325 | 0.88 | KMT2A (0.47) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| Fumaric Acid SCHEMBL1471480 | 0.81 | L3MBTL1 (0.46) | MEN1KMT2APKMPOLBALDH1A1 | |
| Fumaric Acid SCHEMBL27681077 | 0.79 | PTK2 (0.43) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| Fumaric Acid SCHEMBL1473011 | 0.79 | KMT2A (0.46) | MEN1KMT2ASMN1; SMN2PKMPOLB | |
| SCHEMBL1471326 | 0.77 | KMT2A (0.47) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| SCHEMBL1471475 | 0.75 | PKM (0.46) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| Fumaric Acid SCHEMBL1472941 | 0.74 | LMNA (0.46) | MEN1KMT2APKMALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1470849 | 0.74 | PKM (0.45) | MEN1KMT2AMAPK1SMN1; SMN2PKM | |
| Fumaric Acid SCHEMBL1472995 | 0.74 | KDR (0.45) | MEN1KMT2APKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086880-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-04-14 | — | — | US | disclosed |
| US-7915419-B2 | Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086880-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | MEN1 2529/4885KMT2A 1498/4885MAPK1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.